APRIL 18, 2023
Biophytis Announces 2022 Financial Results and 2023 Perspectives €11.1M of available cash and equivalents on December 31, 2022, and financing instruments for a total of €22M allowing financial visibility beyond mid 2024 Positive results of the Phase 2-3 COVA study for the treatment of severe COVID-19 with Sarconeos (BIO101) Early Access Program (EAP) submission in…